Renal Cell Carcinoma Market to Witness an Outstanding Growth by 2025

Renal cell carcinoma, also known as adenocarcinoma, refers to the cancer of kidneys in which malignant cells are found in the renal tubules. It commonly occurs in adults and the geriatric population. Among the types of kidney cancer, renal cell carcinoma is highly prevalent and accounts for 80–90% of the total cases as opposed transitional cell carcinoma which constitutes 5 -10% The renal cell carcinoma market is expected to develop at a decent rate due to the increased incidence reported worldwide. Surgical removal is not the singular solution, especially after the cancer has reached metastatic phase. Therapies with increased effectiveness and limited side-effects such as such as immunotherapy and targeted agents are required in such cases.

Read the Comprehensive Overview of Renal Cell Carcinoma Market: http://www.transparencymarketresearch.com/renal-cell-carcinoma-market.html

Drivers of the renal cell carcinoma market include changing lifestyles, increased levels of smoking & tobacco consumption, misuse of certain painkillers, obesity, and the growing geriatric population. The rising incidence of renal cell carcinoma and comparative lack of availability of effective therapies available point toward the scope of this market. However, the high cost of the medicines and threat of generic entry may hinder the market. Chemotherapy is not effective in renal cell cancer and results in multiple side effects such as nausea & vomiting and weight & hair loss. It can also suppress production of new blood cells, leading to fatigue, anemia, easy bruising or bleeding, and increased risk of infection. Hence, chemotherapy is now replaced with targeted agents and immunotherapies.

The renal cell carcinoma market is segmented according to type of therapy into the following divisions: surgery, chemotherapy, biological therapy, hormone therapy, targeted agents, and radiation therapy. Among these, biological therapy and targeted agents are highly popular. The chemotherapy sector is further divided by therapeutic drug class into the following segments.  RTK (Receptor Tyrosine Kinase) inhibitors, VEGF (Vascular Endothelial Growth Factor) inhibitors, mTOR (mammalian Target of Rapamycin) inhibitors, and TKI (Tyrosine Kinase Inhibitors). Sunitinib is commonly prescribed as it targets multiple receptors which, however may result in multiple side effects, thereby offering scope to emerging low cost drugs.

Geographically, the renal cell carcinoma market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominated the global market due to unhealthy lifestyles, obesity, and hypertension in these regions and excessive smoking in the U.S. Asia and South America exhibit minimal incidence of renal cell carcinoma. Rising awareness and disposable incomes are anticipated to propel the renal cell carcinoma market. Japan and Italy, known for their extensive geriatric population, are predicted to dominate the market. On the other hand, in Asia Pacific, the market is in its developmental phase due to the increasing capacity of individuals to afford high cost medicines and growing geriatric population. Rapid economic development in India, China, Singapore, and Malaysia been projected to motivate the renal cell carcinoma market. According to a study by NCBI named “Racial Disparity in Renal Cell Carcinoma Patient Survival according to Demographic and Clinical Characteristics” published in 2012, the African population runs a comparatively higher risk of developing renal cell carcinoma. Thus, countries with dense African population display potential for the development of renal cell carcinoma market.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25928

Key players in this market include Pfizer, Exelexis Inc., Eisai, GlaxoSmithKline plc. F. Hoffmann-La Roche AG, Novartis International AG, and Bayer AG. Pfizer is leading the market; however GlaxoSmithKline plc. and Novartis are extending their global presence with increased distribution channels.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/